Standard therapy for INCS

Phase 3

Eli Lilly and Company (LLY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

May '27

LLYPhase 3$1.1T

Standard therapy for INCS Phase 3 Est. Readout

Standard therapy for INCS• Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)510

May 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

View Full Landscape

Drug Information

Target Indication

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Clinical Trial

NCT06338995

Last updated: 12/18/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

Insulin LevemirPhase 3

Diabetes Mellitus, Type 1

BamlanivimabPhase 3

COVID-19

Mirikizumab IVPhase 3

Ulcerative Colitis

OlaratumabPhase 3

Metastatic Pancreatic Cancer

Other standard therapy for ADHDPhase 3

Attention Deficit Hyperactivity Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts